Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Matino

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Research and Practice in Thrombosis and Haemostasis|December 11, 2023
Inhibitors in hemophilia: association with surgery plans and outcomes in a retrospective cohort studyOmotola O Olasupo, Charles Nakar, Craig Haddix, et al.
Journal of Thrombosis and Haemostasis : JTH|April 8, 2022
Risk factors for bleeding in people living with hemophilia A and B treated with regular prophylaxis: A systematic review of the literatureFederico Germini, Noella Noronha, Binu Abraham Philip, et al.
Research and Practice in Thrombosis and Haemostasis|April 17, 2023
Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomesAlfonso Iorio, Vance MacDonald, Alexandre Caillaud, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 21, 2024
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in CanadaDavide Matino, Federico Germini, Anthony K C Chan, et al.
Mediators of Inflammation|March 31, 2017
CpG Type A Induction of an Early Protective Environment in Experimental Multiple SclerosisJames Crooks, Marco Gargaro, Carmine Vacca, et al.
Molecular Biosystems|March 27, 2015
Comparative proteomic analysis of two distinct stem-cell populations from human amniotic fluidRita Romani, Francesca Fallarino, Irene Pirisinu, et al.
Immunobiology|October 4, 2014
LPS-conditioned dendritic cells confer endotoxin tolerance contingent on tryptophan catabolismFrancesca Fallarino, Maria T Pallotta, Davide Matino, et al.
Research and Practice in Thrombosis and Haemostasis|March 9, 2023
Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysisIlja Oomen, Ricardo M Camelo, Suely Meireles Rezende, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 17, 2019
Consensus statements on vaccination in patients with haemophilia-Results from the Italian haemophilia and vaccinations (HEVA) projectElena Santagostino, Agostino Riva, Simone Cesaro, et al.
Intensive Care Medicine Experimental|June 24, 2026
Mouse models to study von Willebrand factor in inflammation: a scoping reviewHassan Masood, Veronica DeYoung, Peter Andrisani, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Research and Practice in Thrombosis and Haemostasis|December 11, 2023
Inhibitors in hemophilia: association with surgery plans and outcomes in a retrospective cohort studyOmotola O Olasupo, Charles Nakar, Craig Haddix, et al.
Journal of Thrombosis and Haemostasis : JTH|April 8, 2022
Risk factors for bleeding in people living with hemophilia A and B treated with regular prophylaxis: A systematic review of the literatureFederico Germini, Noella Noronha, Binu Abraham Philip, et al.
Research and Practice in Thrombosis and Haemostasis|April 17, 2023
Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomesAlfonso Iorio, Vance MacDonald, Alexandre Caillaud, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 21, 2024
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in CanadaDavide Matino, Federico Germini, Anthony K C Chan, et al.
Mediators of Inflammation|March 31, 2017
CpG Type A Induction of an Early Protective Environment in Experimental Multiple SclerosisJames Crooks, Marco Gargaro, Carmine Vacca, et al.
Molecular Biosystems|March 27, 2015
Comparative proteomic analysis of two distinct stem-cell populations from human amniotic fluidRita Romani, Francesca Fallarino, Irene Pirisinu, et al.
Immunobiology|October 4, 2014
LPS-conditioned dendritic cells confer endotoxin tolerance contingent on tryptophan catabolismFrancesca Fallarino, Maria T Pallotta, Davide Matino, et al.
Research and Practice in Thrombosis and Haemostasis|March 9, 2023
Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysisIlja Oomen, Ricardo M Camelo, Suely Meireles Rezende, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 17, 2019
Consensus statements on vaccination in patients with haemophilia-Results from the Italian haemophilia and vaccinations (HEVA) projectElena Santagostino, Agostino Riva, Simone Cesaro, et al.
Intensive Care Medicine Experimental|June 24, 2026
Mouse models to study von Willebrand factor in inflammation: a scoping reviewHassan Masood, Veronica DeYoung, Peter Andrisani, et al.
Pageof 7